The addition of bevacizumab to chemotherapy has been shown to improve progression-free survival (PFS) in patients with ovarian cancer, with the greatest benefit observed in those with high-risk disease, and the combination of bevacizumab and olaparib has been approved as a first-line maintenance treatment for patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer.

The results of the study include the finding that bevacizumab is associated with improved PFS in both platinum-resistant and platinum-sensitive recurrent  ...